Storyline
Proteomic and transcriptomic analyses reveal new insights and therapeutic targets in aggressive cancers
Recent studies have advanced understanding of treatment resistance and potential therapies in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
Published 2026-05-26 22:00 UTCUpdated 2026-05-27 00:39 UTC
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Recent studies have advanced understanding of treatment resistance and potential therapies in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
Score total
0.96
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Immune checkpoint inhibitors are standard in NSCLC but resistance remains a major challenge.
- TNBC lacks durable biomarker-guided treatments, creating urgent need for new targets.
- High-throughput proteomics and transcriptomics enable rapid discovery of actionable cancer biology.
Why it matters
- Identifying biomarkers of immune checkpoint inhibitor response can improve patient stratification in NSCLC.
- Understanding molecular drivers in MTUS1-low TNBC may guide development of targeted therapies.
- These insights support precision oncology approaches for aggressive, treatment-resistant cancers.
Continuity snapshot
- Trend status: insufficient_history.
- Continuity stage: seed.
- Current status: open.
- 2 current source-linked posts are attached to this storyline.
All evidence
All evidence
Immune Checkpoint Response Profiles and Resistance Mechanisms in NSCLC Revealed by Circulating Extracellular Vesicle Proteomics
medRxiv (all subjects) · medrxiv.org · 2026-05-27 00:39 UTC
Transcriptomic profile of MTUS1-low TNBC reveals candidate therapeutic strategies.
bioRxiv (all subjects) · biorxiv.org · 2026-05-26 22:00 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- medRxiv (all subjects) (1)
- bioRxiv (all subjects) (1)
Top origin domains (this list)
- medrxiv.org (1)
- biorxiv.org (1)